- Details
- Oliver Sartor interviews Chuck Conroy about Nucleus RadioPharma’s role in radiopharmaceutical manufacturing and distribution. Mr. Conroy explains that Nucleus RadioPharma aims to support both small and large pharmaceutical companies in developing and delivering radioligand therapies. The company is building extensive manufacturing facilities across the US, with plans to create more capacity than c...
|
- Details
- Sergio Calvo discusses GE's role in theranostics, emphasizing their broad portfolio spanning cyclotrons, radiosynthesis modules, and imaging devices. He highlights GE's recent acquisition of MIM Software to enhance flexibility in image analysis for diverse radioligand therapies. Mr. Calvo predicts significant growth in the field, expecting a twentyfold increase in patient treatments within a decad...
|
- Details
- David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology. He outlines ongoing collaborations between cooperative groups and industry partners to develop and validate AI tools for cancer diagnosis and treatment prediction. Dr. McConkey emphasizes the importance of open access data, quality control, and rigorous validation in AI re...
|
- Details
- Roger Li discusses findings from a patient panel at the BCAN Think Tank, focusing on decision-making in BCG-unresponsive and muscle-invasive bladder cancer treatment. He emphasizes the emotional journey patients undergo and the importance of empowering them with information. Dr. Li highlights several patient stories, demonstrating diverse treatment choices ranging from bladder-sparing approaches t...
|
- Details
- Oliver Sartor interviews John Valliant about the potential of radiopharmaceuticals in cancer treatment. Dr. Valliant discusses the advantages of targeted radiation therapy, particularly using Actinium-225, highlighting its efficacy and potential for combination therapies. He emphasizes the unique ability of radiopharmaceuticals to combine imaging and treatment, allowing for better patient selectio...
|
- Details
- Arnav Srivastava discusses his research on out-of-pocket costs for prostate cancer screening follow-up among privately insured men. The study reveals that by 2020, 80% of patients face out-of-pocket expenses for diagnostic testing, with costs rising significantly over time. Patients undergoing both MRI and biopsy can expect to pay over $600. Dr. Srivastava highlights the potential implications, in...
|
- Details
- Oliver Sartor interviews Anna Karmann about the potential of radiopharmaceuticals in cancer treatment. Dr. Karmann discusses the advantages of Lead-212, highlighting its alpha-emitting properties, short half-life, and potential for frequent dosing strategies. She emphasizes the unique benefits of Lead-212, including its synergy with the immune system and logistical advantages in drug delivery. Dr....
|
- Details
- Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly for commercially insured patients. Dr. Joyce highlights disparities in costs based on factors like age, race, and income. He emphasizes the importance of addressing financial toxicity in patient care, no...
|
- Details
- Amy Reed discusses a study on diversity, equity, and inclusion in urolithiasis clinical trials over the past two decades. The research analyzes 180 trials, examining patient enrollment by race, ethnicity, and sex. Using a representation quotient, the study finds that white patients are adequately represented, Black patients are overrepresented, while Hispanic and mixed-race patients are underrepre...
|
- Details
- Mark Ball and Jessica Hsueh discuss a study on using GPT-4 for data extraction from renal surgery operative notes. The research compares GPT-4's performance to human-curated data across five variables: laterality, surgery type, approach, estimated blood loss, and ischemia time. Results show high accuracy for categorical variables but lower accuracy for continuous variables and heterogeneously writ...
|
